A new moment for facing dengue?

Pathogens and Global Health

Volumn 109, Issue 1, 2015, Pages 2-3

  Guzman, Maria G ^a  

^a Department of Virology PAHO WHO Collaborating Center for the Study of Dengue and its Vector Pedro Kouri Tropical medicine Institute of Havana   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE;

DENGUE; DISEASE TRANSMISSION; HEALTH CARE PLANNING; HUMAN; IMMUNE SYSTEM; NOTE; VACCINATION; WORLD HEALTH ORGANIZATION; DENGUE VIRUS; FEMALE; GENETICS; MALE;

DENGUE; DENGUE VACCINES; DENGUE VIRUS; FEMALE; HUMANS; MALE;

EID: 84928230655     PISSN: 20477724     EISSN: 20477732     Source Type: Journal    
DOI: 10.1179/2047772415Z.000000000247     Document Type: Note

References (7)

1. Capeding MR, Tran NH, Hadinegoro SR, Ismail HIM, Chotpitayasunondh T, Chua MN, et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo controlled trial. The Lancet. 2014;384:1358-65.
2. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. The New Eng J Med. 2014.
3. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. The Lancet. 2012;1-9.
4. WHO. Global strategy for dengue prevention and control.: World Health Organization; ISBN 978 92 4 150403 4.2012.
5. Rodriguez-Barraquer I, Miery-Teran-Romero L, Burke DS, Cummings DAT. Challenges in the interpretation of dengue vaccine trial results. PloS NTD. 2013;7:1-3.
6. Mahalingam S, Herring BL, Halstead SB. Call to action for dengue vaccine failure. Emerging Inf Dis. 2013;19: 1335-6.
7. Halstead SB. Identifying protective dengue vaccines: Guide to mastering an empirical process. Vaccine. 2013;31: 4501-7